Head and neck sarcomas: A single institute series

Publication date: February 2017
Source:Oral Oncology, Volume 65
Author(s): Leandros-Vassilios Vassiliou, Bagrat Lalabekyan, Amrita Jay, Colin Liew, Jeremy Whelan, Laurence Newman, Nicholas Kalavrezos
BackgroundSarcomas are tumours of mesenchymal origin, accounting for 1% of all malignancies.MethodsThis is a retrospective analysis of 107 head and neck sarcoma cases, treated over a period of thirteen years.ResultsFifty-four patients had with craniofacial bone sarcomas (BSs) (male: 33; female: 21) with high grade osteosarcoma being the most predominant type. The soft tissue sarcomas (STS) (53 patients; male: 28, female: 25) were histologically diverse with rhabdomyosarcomas and myxofibrosarcomas being the predominant types. The majority of BSs were managed with neoadjuvant chemotherapy followed by surgery, whereas in STSs treatment included predominantly surgery followed by radiotherapy. Overall survival estimates were 79% at 2years and 64% at 5years (mean follow-up period was 48months).ConclusionsThe mesenchymal origin of sarcomas, the pattern of disease spread and the different extent of cancellous bone infiltration in contrast to epithelial tumours, dictate distinct principles for surgical clearance.



http://ift.tt/2gRQIm1